Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

9.0K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
9.0K
Abnormal Proliferation02:23

Abnormal Proliferation

5.3K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.3K
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

9.1K
The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
9.1K
Cells of the Innate Immune Response01:28

Cells of the Innate Immune Response

9.9K
The innate immune response is an immediate and non-specific response against pathogens, acting swiftly to prevent the spread of infections. The primary cells involved in this response are phagocytes and natural killer (NK) cells.
Phagocytes
Phagocytes police the peripheral tissues by removing cellular debris and responding to the invasion of foreign substances or pathogens. Many phagocytes attack and remove microorganisms even before lymphocytes detect them. The human body has two general...
9.9K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

7.6K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.6K
Overview of Cell Death01:30

Overview of Cell Death

10.7K
Cell death is an essential process where the body gets rid of old or damaged cells. Cell proliferation and death need to be balanced, as an imbalance between the two may lead to cancer or autoimmune diseases.
Cell death was observed in the early 19th century, but there was no experimental evidence to prove it. In 1842, Carl Vogt first discovered cell death in a metamorphic toad; however, it was not termed ‘cell death.’ Scientists discovered different cell death pathways only in the...
10.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Chromoanagenesis in Myelodysplastic Syndromes Is Associated With Highly Complex Karyotype, TP53 Disruption, and Dismal Prognosis.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc·2026
Same author

Application of Hi-C sequencing to detect oncogene rearrangements for diagnosis and treatment of large B-cell lymphoma.

Blood advances·2026
Same author

Loss of systemic anti-viral immunity and LMP1-driven suppressive myeloid tumour niches converge to shape the immunobiology of Epstein-Barr virus-positive diffuse large B-cell lymphoma.

Leukemia·2026
Same author

Comprehensive Cytogenomic Profiling of T-Lymphoblastic Leukemia Using Optical Genome Mapping, Karyotyping, and Next-Generation Sequencing.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc·2026
Same author

Isolated <i>KRAS</i> and <i>NRAS</i> mutations in adults with monocytosis and/or cytopenia(s).

Haematologica·2025
Same author

Proinflammatory GSDMD activation in live macrophages and DLBCL cells marks cognate interactions and better prognosis.

Blood advances·2025

Related Experiment Video

Updated: Mar 7, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.3K

Targeting the programmed death-1 pathway in lymphoid neoplasms.

Chi Young Ok1, Ken H Young1

  • 1The Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Cancer Treatment Reviews
|March 1, 2017
PubMed
Summary

Programmed death-1 (PD-1) therapy shows promise for lymphoid neoplasms. Clinical trials are expanding the use of anti-PD-1 agents to improve treatment responses in patients with these cancers.

Keywords:
Immune checkpointLymphoid neoplasmsPD-1PD-L1PD-L2

More Related Videos

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

6.2K
Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes
09:40

Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes

Published on: September 28, 2018

15.9K

Related Experiment Videos

Last Updated: Mar 7, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.3K
Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

6.2K
Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes
09:40

Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes

Published on: September 28, 2018

15.9K

Area of Science:

  • Immunology
  • Oncology
  • Molecular Biology

Background:

  • Programmed death-1 (PD-1) is a co-inhibitory molecule on T cells that regulates immune responses.
  • PD-1 ligands, programmed death ligand-1 (PD-L1) and -2 (PD-L2), can suppress anti-tumor immunity in lymphoid neoplasms.
  • Tumor PD-L1 expression is influenced by various intrinsic and extrinsic factors, including genetic aberrations and inflammatory signals.

Purpose of the Study:

  • To review current clinical trials evaluating anti-PD-1 and anti-PD-L1 therapies in lymphoid neoplasms.
  • To summarize the efficacy of PD-1 pathway inhibitors in treating these cancers.
  • To explore the potential expansion of PD-1-targeted therapies for a broader patient population.

Main Methods:

  • Review of current clinical trials involving anti-PD-1 or anti-PD-L1 drugs.
  • Analysis of treatment response rates in patients with lymphoid neoplasms.
  • Synthesis of data on PD-1 pathway modulation in cancer treatment.

Main Results:

  • Anti-PD-1 therapy has demonstrated improved response rates in lymphoid neoplasms, notably in classical Hodgkin lymphoma.
  • Therapeutic strategies involving PD-1 inhibitors are being extended to other lymphoma subtypes.
  • Ongoing clinical trials aim to further elucidate the benefits of PD-1 pathway inhibition.

Conclusions:

  • PD-1 pathway inhibitors represent a significant advancement in treating lymphoid neoplasms.
  • Expanding PD-1-targeted therapies holds promise for improving outcomes in a wider range of patients.
  • Further research will broaden the application of these immunotherapies in hematologic malignancies.